Breaking News, Financial News

Financial Reports: Jubilant Life Sciences 1Q12

CMO, Discovery/Development revenues rise

Jubilant Life Sciences 1Q12

1Q Revenues: $209 million (+16%)

1Q Earnings: $17 million (+53%)

Comments: CMO revenues accounted for 16% of total revenues ($33 million), while Drug Discovery and Development Services accounted for 5% ($11 million). Life Science Products accounted for 78% of 1Q sales ($163 million), up 19% from the previous year, driven by volume growth and higher pricing. Generic revenues (part of Life Science Products) were up 33% to $29 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters